These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10570186)

  • 1. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.
    Wang H; Cai Q; Zeng X; Yu D; Agrawal S; Zhang R
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):13989-94. PubMed ID: 10570186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
    Wang H; Hang J; Shi Z; Li M; Yu D; Kandimalla ER; Agrawal S; Zhang R
    Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
    Nesterova M; Cho-Chung YS
    Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):423-33. PubMed ID: 11198926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS; Cho-Chung YS
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
    Agrawal S; Kandimalla ER; Yu D; Ball R; Lombardi G; Lucas T; Dexter DL; Hollister BA; Chen SF
    Int J Oncol; 2002 Jul; 21(1):65-72. PubMed ID: 12063551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
    Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
    Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.
    Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Bianco AR; Jiang Z; Agrawal S; Ciardiello F
    Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12586-91. PubMed ID: 9356493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense depletion of RIalpha subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells.
    Srivastava RK; Srivastava AR; Park YG; Agrawal S; Cho-Chung YS
    Breast Cancer Res Treat; 1998 May; 49(2):97-107. PubMed ID: 9696392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
    Tortora G; Bianco R; Damiano V; Fontanini G; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Jun; 6(6):2506-12. PubMed ID: 10873106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
    J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention with protein kinase A RIalpha antisense in DMBA-mammary carcinogenesis.
    Nesterova MV; Cho-Chung YS
    Ann N Y Acad Sci; 2005 Nov; 1058():255-64. PubMed ID: 16394142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
    Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
    Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
    Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
    Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RIalpha regulatory subunit.
    Neary CL; Cho-Chung YS
    Oncogene; 2001 Nov; 20(55):8019-24. PubMed ID: 11753685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.
    Mani S; Goel S; Nesterova M; Martin RM; Grindel JM; Rothenberg ML; Zhang R; Tortora G; Cho-Chung YS
    Ann N Y Acad Sci; 2003 Dec; 1002():252-62. PubMed ID: 14751840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.